[
  {
    "ts": null,
    "headline": "Humana Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
    "summary": "Humana Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=674fd619244242ed7d6c4e1f2cf0e56d8ec55485522529e68b78122da5ee715f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755017820,
      "headline": "Humana Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
      "id": 136361266,
      "image": "",
      "related": "HUM",
      "source": "MarketWatch",
      "summary": "Humana Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=674fd619244242ed7d6c4e1f2cf0e56d8ec55485522529e68b78122da5ee715f"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Humana (HUM) is a Strong Value Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=f3ac00d0556503c6ad1b5c3272aebdae9a33d32c317f4c94246334ed15416f04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755006003,
      "headline": "Here's Why Humana (HUM) is a Strong Value Stock",
      "id": 136321032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HUM",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=f3ac00d0556503c6ad1b5c3272aebdae9a33d32c317f4c94246334ed15416f04"
    }
  },
  {
    "ts": null,
    "headline": "HUM Q2 Deep Dive: Pharmacy Strength, Medicaid Expansion, and Guidance Lift",
    "summary": "Health insurance company Humana (NYSE:HUM) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 9.6% year on year to $32.39 billion. The company’s full-year revenue guidance of $128 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $6.27 per share was 6.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=5e8b44d6d760b408a6e927a11344f4a23c591fa3666edce1fcc21bae14462b67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754974807,
      "headline": "HUM Q2 Deep Dive: Pharmacy Strength, Medicaid Expansion, and Guidance Lift",
      "id": 136316420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HUM",
      "source": "Yahoo",
      "summary": "Health insurance company Humana (NYSE:HUM) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 9.6% year on year to $32.39 billion. The company’s full-year revenue guidance of $128 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $6.27 per share was 6.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=5e8b44d6d760b408a6e927a11344f4a23c591fa3666edce1fcc21bae14462b67"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Humana’s Q2 Earnings Call",
    "summary": "Humana delivered a second quarter that outpaced Wall Street’s expectations, with management highlighting CenterWell Pharmacy’s strong performance and stable medical cost trends as key drivers. CEO James Rechtin attributed the positive results to “better-than-expected individual Medicare Advantage membership” and a rebound of members who returned to Humana after trying other plans. Management also pointed to efforts streamlining the prior authorization process and investments in improving the mem",
    "url": "https://finnhub.io/api/news?id=41d1c9a091d459061ab98ec2e221e7c8b4f6c855adb823946f1b8c4175936f42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754974250,
      "headline": "The Top 5 Analyst Questions From Humana’s Q2 Earnings Call",
      "id": 136316421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HUM",
      "source": "Yahoo",
      "summary": "Humana delivered a second quarter that outpaced Wall Street’s expectations, with management highlighting CenterWell Pharmacy’s strong performance and stable medical cost trends as key drivers. CEO James Rechtin attributed the positive results to “better-than-expected individual Medicare Advantage membership” and a rebound of members who returned to Humana after trying other plans. Management also pointed to efforts streamlining the prior authorization process and investments in improving the mem",
      "url": "https://finnhub.io/api/news?id=41d1c9a091d459061ab98ec2e221e7c8b4f6c855adb823946f1b8c4175936f42"
    }
  }
]